Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Angelo Antonini

Showing results (11-20 of 494) with videos related to

Pageof 50
Sort By:
Neuropsychiatric Disease and Treatment|June 10, 2011
Once-daily pramipexole for the treatment of early and advanced idiopathic Parkinson's disease: implications for patientsAngelo Antonini, Daniela Calandrella
The Lancet. Neurology|August 21, 2007
Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's diseaseAngelo Antonini, Werner Poewe
Parkinsonism & Related Disorders|December 15, 2011
Pulsatile or continuous dopaminomimetic strategies in Parkinson's diseaseDaniela Calandrella, Angelo Antonini
Neurology|October 19, 2013
Author ResponseAngelo Antonini, Roger Albin
Parkinsonism & Related Disorders|February 4, 2010
Pros and cons of apomorphine and L-dopa continuous infusion in advanced Parkinson's diseaseAngelo Antonini, Per Odin
Drug Safety|May 23, 2009
Behavioural adverse effects of dopaminergic treatments in Parkinson's disease: incidence, neurobiological basis, management and preventionAngelo Antonini, Roberto Cilia
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|April 22, 2009
Dopamine agonist-based strategies in the treatment of Parkinson's diseaseAngelo Antonini, Paolo Barone
Movement Disorders : Official Journal of the Movement Disorder Society|December 6, 2014
Novel formulations and modes of delivery of levodopaWerner Poewe, Angelo Antonini
Expert Review of Neurotherapeutics|June 10, 2011
Pathological gambling in Parkinson's disease: disease related or drug related?Daniela Calandrella, Angelo Antonini
The Lancet. Neurology|October 24, 2015
Targeting pain in Parkinson's diseaseAngelo Antonini, Michele Tinazzi
Pageof 50

Showing results (11-20 of 494) with videos related to

Sort By:
Pageof 50
Neuropsychiatric Disease and Treatment|June 10, 2011
Once-daily pramipexole for the treatment of early and advanced idiopathic Parkinson's disease: implications for patientsAngelo Antonini, Daniela Calandrella
The Lancet. Neurology|August 21, 2007
Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's diseaseAngelo Antonini, Werner Poewe
Parkinsonism & Related Disorders|December 15, 2011
Pulsatile or continuous dopaminomimetic strategies in Parkinson's diseaseDaniela Calandrella, Angelo Antonini
Neurology|October 19, 2013
Author ResponseAngelo Antonini, Roger Albin
Parkinsonism & Related Disorders|February 4, 2010
Pros and cons of apomorphine and L-dopa continuous infusion in advanced Parkinson's diseaseAngelo Antonini, Per Odin
Drug Safety|May 23, 2009
Behavioural adverse effects of dopaminergic treatments in Parkinson's disease: incidence, neurobiological basis, management and preventionAngelo Antonini, Roberto Cilia
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|April 22, 2009
Dopamine agonist-based strategies in the treatment of Parkinson's diseaseAngelo Antonini, Paolo Barone
Movement Disorders : Official Journal of the Movement Disorder Society|December 6, 2014
Novel formulations and modes of delivery of levodopaWerner Poewe, Angelo Antonini
Expert Review of Neurotherapeutics|June 10, 2011
Pathological gambling in Parkinson's disease: disease related or drug related?Daniela Calandrella, Angelo Antonini
The Lancet. Neurology|October 24, 2015
Targeting pain in Parkinson's diseaseAngelo Antonini, Michele Tinazzi
Pageof 50